Glitos Plus (pioglitazone + metformin): Uses, Dosage & Side Effects

What it's for (Indications)

Pioglitazone and metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.
This fixed-dose combination is particularly suited for individuals whose hyperglycemia is not adequately controlled with metformin or pioglitazone monotherapy, or for those already receiving separate doses of pioglitazone and metformin who would benefit from a more convenient, single-tablet regimen.
The combined therapy addresses multiple pathophysiological defects of type 2 diabetes: metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, while pioglitazone, a thiazolidinedione (TZD), functions as a selective agonist for peroxisome proliferator-activated receptor gamma (PPAR-gamma), enhancing insulin sensitivity in adipose tissue, skeletal muscle, and liver.
This complementary action contributes to a more comprehensive glucose-lowering effect.
It is important to note that this medication is not indicated for the treatment of type 1 diabetes mellitus or for the management of diabetic ketoacidosis.

Dosage Information

Type	Guideline
Standard	Dosage of pioglitazone and metformin combination therapy must be individualized based on the patient's current treatment regimen, glycemic control, and tolerability, while not exceeding the maximum recommended daily doses of each component. This combination is generally administered once or twice daily with meals to minimize gastrointestinal side effects associated with metformin. For patients inadequately controlled on metformin monotherapy, the initial dose should be a low dose of pioglitazone added to the existing metformin dose. For patients inadequately controlled on pioglitazone monotherapy, a low dose of metformin should be added to the existing pioglitazone dose. When switching from separate tablets of pioglitazone and metformin, the combination tablet should be started at doses providing approximately the same daily dose of each component. Dosage adjustments should be gradual, typically at 2 to 4-week intervals, to assess glycemic response and tolerability. Renal function must be assessed prior to initiation and periodically thereafter due to the metformin component; initiation is contraindicated in patients with an eGFR below 30 mL/min/1.73 m² and not recommended in those with an eGFR between 30-45 mL/min/1.73 m². Hepatic function should also be monitored.

Type

Guideline

Standard

Dosage of pioglitazone and metformin combination therapy must be individualized based on the patient's current treatment regimen, glycemic control, and tolerability, while not exceeding the maximum recommended daily doses of each component. This combination is generally administered once or twice daily with meals to minimize gastrointestinal side effects associated with metformin. For patients inadequately controlled on metformin monotherapy, the initial dose should be a low dose of pioglitazone added to the existing metformin dose. For patients inadequately controlled on pioglitazone monotherapy, a low dose of metformin should be added to the existing pioglitazone dose. When switching from separate tablets of pioglitazone and metformin, the combination tablet should be started at doses providing approximately the same daily dose of each component. Dosage adjustments should be gradual, typically at 2 to 4-week intervals, to assess glycemic response and tolerability. Renal function must be assessed prior to initiation and periodically thereafter due to the metformin component; initiation is contraindicated in patients with an eGFR below 30 mL/min/1.73 m² and not recommended in those with an eGFR between 30-45 mL/min/1.73 m². Hepatic function should also be monitored.

Safety & Warnings

Common Side Effects

The most common side effects associated with pioglitazone and metformin combination therapy are largely reflective of its individual components.
For the metformin component, gastrointestinal disturbances such as diarrhea, nausea, vomiting, abdominal discomfort, and flatulence are frequently reported, especially during initiation and dose titration.
A metallic taste is also common.
For the pioglitazone component, common adverse reactions include upper respiratory tract infection, headache, sinusitis, and myalgia.
Weight gain and edema (fluid retention) are also frequently observed with pioglitazone, which may contribute to or exacerbate heart failure.
Less common but serious adverse events include lactic acidosis, a rare but potentially fatal complication primarily associated with metformin, especially in patients with predisposing conditions such as renal impairment or acute heart failure.
Pioglitazone has been linked to an increased risk of congestive heart failure, bone fractures (particularly in women), and a small increased risk of bladder cancer with prolonged use.
Macular edema has also been reported with pioglitazone.
Hypoglycemia is generally uncommon when this combination is used alone but the risk increases significantly when combined with insulin or insulin secretagogues (e.
g.
, sulfonylureas).
Vitamin B12 deficiency may also occur with long-term metformin use.

Serious Warnings

Black Box Warning: WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS. Thiazolidinediones, including pioglitazone, can cause or exacerbate congestive heart failure in some patients. After initiation and dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea). Lactic acidosis is also a serious risk associated with metformin.
This combination medication carries significant warnings that require careful consideration.
A **Black Box Warning** exists for pioglitazone regarding its potential to cause or exacerbate congestive heart failure (CHF).
Patients should be closely monitored for signs and symptoms of heart failure (e.
g.
, rapid weight gain, dyspnea, edema), and pioglitazone is contraindicated in patients with New York Heart Association (NYHA) Class III or IV heart failure.
**Lactic Acidosis:** Metformin can cause lactic acidosis, a rare but serious metabolic complication that can be fatal if not promptly treated.
Risk factors include renal impairment, concomitant conditions that may cause hypoxemia (e.
g.
, acute congestive heart failure, sepsis, acute myocardial infarction), excessive alcohol intake, hepatic impairment, and dehydration.
Renal function should be assessed before starting therapy and regularly thereafter.
**Bladder Cancer:** An increased risk of bladder cancer has been observed with pioglitazone use, particularly with longer duration and higher cumulative doses.
A thorough risk-benefit assessment should precede treatment initiation, especially in patients with a history of bladder cancer or risk factors for bladder cancer.
**Bone Fractures:** An increased incidence of bone fractures in female patients has been reported with pioglitazone.
**Macular Edema:** Pioglitazone can cause or worsen macular edema, requiring regular ophthalmologic examination, particularly in patients reporting visual disturbances.
**Hypoglycemia:** The risk of hypoglycemia is increased when used in combination with insulin or insulin secretagogues.
**Vitamin B12 Deficiency:** Metformin may decrease vitamin B12 levels, requiring periodic monitoring.
**Ovulation:** Pioglitazone may cause ovulation in premenopausal anovulatory women, necessitating contraception counseling.
**Radiological Studies:** Temporarily discontinue metformin for 48 hours in patients undergoing iodinated contrast imaging procedures due to the risk of contrast-induced nephropathy and subsequent lactic acidosis.

How it Works (Mechanism of Action)

The therapeutic efficacy of pioglitazone and metformin derives from the distinct yet complementary mechanisms of action of its two active components. **Metformin**, a biguanide, primarily acts by reducing hepatic glucose production. It achieves this by decreasing both gluconeogenesis and glycogenolysis in the liver. Additionally, metformin improves insulin sensitivity in peripheral tissues, such as skeletal muscle, by increasing glucose uptake and utilization, without directly stimulating insulin secretion. It also has a minor effect on reducing intestinal glucose absorption. The net effect is a significant reduction in fasting and postprandial blood glucose levels. **Pioglitazone**, a member of the thiazolidinedione (TZD) class, functions as a highly selective agonist for peroxisome proliferator-activated receptor gamma (PPAR-gamma). These nuclear receptors are predominantly found in adipose tissue, skeletal muscle, and liver cells. Upon activation, PPAR-gamma modulates the transcription of insulin-responsive genes involved in the control of glucose and lipid metabolism. This leads to an increase in insulin sensitivity in these target tissues, resulting in enhanced peripheral glucose uptake and utilization, reduced hepatic glucose production, and improved lipid profiles. By ameliorating insulin resistance, pioglitazone helps to restore the body's natural response to insulin, thereby lowering blood glucose levels. The combination provides a synergistic approach to managing hyperglycemia in type 2 diabetes.